U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C24H36O3
Molecular Weight 372.5417
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NABILONE

SMILES

CCCCCCC(C)(C)c1cc(c2[C@]3([H])CC(=O)CC[C@@]3([H])C(C)(C)Oc2c1)O

InChI

InChIKey=GECBBEABIDMGGL-RTBURBONSA-N
InChI=1S/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1

HIDE SMILES / InChI

Molecular Formula C24H36O3
Molecular Weight 372.5417
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Nabilone is a synthetic cannabinoid approved under the brand name cesamet for treatment of severe nausea and vomiting associated with cancer chemotherapy. Nabilone is an orally active which, like other cannabinoids, has complex effects on the central nervous system (CNS). It has been suggested that the antiemetic effect of nabilone is caused by interaction with the cannabinoid receptor system, i.e. the CB (1) receptor, which has been discovered in neural tissues.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.29 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
CESAMET

Approved Use

Cesamet capsules are indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. This restriction is required because a substantial proportion of any group of patients treated with Cesamet can be expected to experience disturbing psychotomimetic reactions not observed with other antiemetic agents. Because of its potential to alter the mental state, Cesamet is intended for use under circumstances that permit close supervision of the patient by a responsible individual particularly during initial use of Cesamet and during dose adjustments. Cesamet contains nabilone, which is controlled in Schedule II of the Controlled Substances Act. Schedule II substances have a high potential for abuse. Prescriptions for Cesamet should be limited to the amount necessary for a single cycle of chemotherapy (i.e., a few days). Cesamet capsules are not intended to be used on as needed basis or as a first antiemetic product prescribed for a patient. As with all controlled drugs, prescribers should monitor patients receiving nabilone for signs of excessive use, abuse and misuse. Patients who may be at increased risk for substance abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse) or mental illness.

Launch Date

5.04403198E11
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
345 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NABILONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
90 ng × h/mL
0.5 mg single, intravenous
dose: 0.5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
NABILONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NABILONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.7 h
0.5 mg single, intravenous
dose: 0.5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
NABILONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
2 mg 1 times / day single, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: single
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 18-77
n = 67
Health Status: unhealthy
Condition: cancer
Age Group: 18-77
Sex: M+F
Population Size: 67
Sources:
Disc. AE: Hallucinations...
AEs leading to
discontinuation/dose reduction:
Hallucinations
Sources:
2 mg 2 times / day multiple, oral
Recommended
Dose: 2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2 mg, 2 times / day
Sources: Page: Protocol 28
unhealthy, 20-78
n = 24
Health Status: unhealthy
Condition: cancer
Age Group: 20-78
Sex: M+F
Population Size: 24
Sources: Page: Protocol 28
Disc. AE: Intoxication, Orthostatic hypotension...
AEs leading to
discontinuation/dose reduction:
Intoxication
Orthostatic hypotension
Drowsiness
Dizziness
Sources: Page: Protocol 28
8 mg 1 times / day multiple, oral
Highest studied dose
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
healthy, 30±10
n = 11
Health Status: healthy
Age Group: 30±10
Sex: M+F
Population Size: 11
Sources:
AEs

AEs

AESignificanceDosePopulation
Hallucinations Disc. AE
2 mg 1 times / day single, oral
Recommended
Dose: 2 mg, 1 times / day
Route: oral
Route: single
Dose: 2 mg, 1 times / day
Sources:
unhealthy, 18-77
n = 67
Health Status: unhealthy
Condition: cancer
Age Group: 18-77
Sex: M+F
Population Size: 67
Sources:
Dizziness Disc. AE
2 mg 2 times / day multiple, oral
Recommended
Dose: 2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2 mg, 2 times / day
Sources: Page: Protocol 28
unhealthy, 20-78
n = 24
Health Status: unhealthy
Condition: cancer
Age Group: 20-78
Sex: M+F
Population Size: 24
Sources: Page: Protocol 28
Drowsiness Disc. AE
2 mg 2 times / day multiple, oral
Recommended
Dose: 2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2 mg, 2 times / day
Sources: Page: Protocol 28
unhealthy, 20-78
n = 24
Health Status: unhealthy
Condition: cancer
Age Group: 20-78
Sex: M+F
Population Size: 24
Sources: Page: Protocol 28
Intoxication Disc. AE
2 mg 2 times / day multiple, oral
Recommended
Dose: 2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2 mg, 2 times / day
Sources: Page: Protocol 28
unhealthy, 20-78
n = 24
Health Status: unhealthy
Condition: cancer
Age Group: 20-78
Sex: M+F
Population Size: 24
Sources: Page: Protocol 28
Orthostatic hypotension Disc. AE
2 mg 2 times / day multiple, oral
Recommended
Dose: 2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2 mg, 2 times / day
Sources: Page: Protocol 28
unhealthy, 20-78
n = 24
Health Status: unhealthy
Condition: cancer
Age Group: 20-78
Sex: M+F
Population Size: 24
Sources: Page: Protocol 28
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy.
1979 Jun 7
Nabilone: an effective antiemetic in patients receiving cancer chemotherapy.
1981 Aug-Sep
Effects of the synthetic cannabinoid nabilone on spatial learning and hippocampal neurotransmission.
2003 Jun
Determination of nabilone in bulk powders and capsules by high-performance liquid chromatography/tandem mass spectrometry.
2004
Two cases of "cannabis acute psychosis" following the administration of oral cannabis.
2005 Apr 1
Cannabinoids in medicine: A review of their therapeutic potential.
2006 Apr 21
Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.
2007 Jun
Reassessment of the role of cannabinoids in the management of pain.
2007 Oct
A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting.
2008 Feb
Cannabinoids in the management of difficult to treat pain.
2008 Feb
Nabilone for the treatment of pain in fibromyalgia.
2008 Feb
Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain.
2008 Jan
The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation.
2008 Jan
Are cannabinoids a new treatment option for pain in patients with fibromyalgia?
2008 Jul
[What sense in cannabinoid use as regulated by Italian DM 18/04/07? Pharmacological and legal considerations].
2008 Jun
Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring.
2008 Mar
A treatment algorithm for neuropathic pain: an update.
2009 Dec
Fungal biotransformation of cannabinoids: potential for new effective drugs.
2009 Mar
Cannabinoids, endocannabinoids, and related analogs in inflammation.
2009 Mar
The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD).
2009 Winter
Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists.
2010
Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines.
2010
Functional role of cannabinoid receptors in urinary bladder.
2010 Jan-Mar
Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain.
2010 Mar 17
New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids.
2010 Mar 3
Patents

Sample Use Guides

The usual adult dosage is 1 or 2 mg b.i.d. On the day of chemotherapy, the initial dose should be given 1 to 3 hours before the chemotherapeutic agent is administered. To minimize side effects, it is recommended that the lower starting dose be used and that the dose be increased as necessary. A dose of 1 or 2 mg the night before may be useful. The maximum recommended daily dose is 6 mg given in divided doses t.i.d. Cesamet (nabilone) may be administered 2 or 3 times daily during the entire course of each cycle of chemotherapy and, if needed, for 48 hours after the last dose of each cycle of chemotherapy.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 12:53:59 UTC 2021
Edited
by admin
on Sat Jun 26 12:53:59 UTC 2021
Record UNII
2N4O9L084N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NABILONE
INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
NABILONE [MI]
Common Name English
NABILONE [VANDF]
Common Name English
NABILONE [WHO-DD]
Common Name English
NABILONE [INN]
Common Name English
(+/-)-3-(1,1-DIMETHYLHEPTYL-6,6A.BETA.,7,8,10,10A.ALPHA.-HEXAHYDRO-1-HYDROXY-6,6-DIMETHYL-9H-DIBENZO(B,D)PYRAN-9-ONE
Common Name English
9H-DIBENZO(B,D)PYRAN-9-ONE, 3-(1,1-DIMETHYLHEPTYL)-6,6A,7,8,10,10A-HEXAHYDRO-1-HYDROXY-6,6-DIMETHYL-, TRANS-, (+/-)-
Common Name English
CESAMET
Brand Name English
NABILONE [ORANGE BOOK]
Common Name English
CPD-109514
Code English
NABILONE [USAN]
Common Name English
NABILONE [MART.]
Common Name English
CPD 109514
Code English
Classification Tree Code System Code
NCI_THESAURUS C267
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
LIVERTOX 657
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
NDF-RT N0000008010
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
DEA NO. 7379
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
NDF-RT N0000175782
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
WHO-VATC QA04AD11
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
EU-Orphan Drug Nabilone
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
WHO-ATC A04AD11
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
Code System Code Type Description
PUBCHEM
5284592
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
PRIMARY
CAS
51022-71-0
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
PRIMARY
MERCK INDEX
M7697
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL2218896
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
PRIMARY
EVMPD
SUB09104MIG
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
PRIMARY
MESH
C011941
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
PRIMARY
FDA UNII
2N4O9L084N
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
PRIMARY
EPA CompTox
51022-71-0
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
PRIMARY
RXCUI
31447
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
PRIMARY RxNorm
DRUG BANK
DB00486
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
PRIMARY
INN
3930
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
PRIMARY
NCI_THESAURUS
C1171
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
PRIMARY
DRUG CENTRAL
1862
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
PRIMARY
WIKIPEDIA
NABILONE
Created by admin on Sat Jun 26 12:53:59 UTC 2021 , Edited by admin on Sat Jun 26 12:53:59 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> AGONIST
Ki
TARGET -> AGONIST
Related Record Type Details
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC